WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000027433) CHIMERIC ANTI-CD20 ANTIBODY TREATMENT OF PATIENTS RECEIVING BMT OR PBSC TRANSPLANTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/027433    International Application No.:    PCT/US1999/024012
Publication Date: 18.05.2000 International Filing Date: 09.11.1999
Chapter 2 Demand Filed:    05.06.2000    
IPC:
C07K 16/28 (2006.01)
Applicants: IDEC PHARMACEUTICALS CORPORATION [US/US]; 11011 Torreyana Road San Diego, CA 92121 (US) (For All Designated States Except US).
GRILLO-LOPEZ, Antonio, J. [US/US]; (US) (For US Only).
LEONARD, John, E. [US/US]; (US) (For US Only)
Inventors: GRILLO-LOPEZ, Antonio, J.; (US).
LEONARD, John, E.; (US)
Agent: GESS, E., Joseph; Burns, Doane, Swecker & Mathis L.L.P. P.O. Box 1404 Alexandria, VA 22313-1404 (US)
Priority Data:
60/107,657 09.11.1998 US
Title (EN) CHIMERIC ANTI-CD20 ANTIBODY TREATMENT OF PATIENTS RECEIVING BMT OR PBSC TRANSPLANTS
(FR) TRAITEMENT PAR ANTICORPS CHIMERE ANTI-CD20, DE PATIENTS RECEVEURS DE GREFFES DE MOELLE OSSEUSE OU DE CELLULES SOUCHES DE SANG PERIPHERIQUE
Abstract: front page image
(EN)The use of a chimeric anti-CD20 antibody, RITUXAN$m(3), as an $i(in vivo) or $i(in vitro) purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
(FR)L'invention concerne l'utilisation d'un anticorps chimère anti-CD20, RITUXAN$m(3), en tant qu'agent de purge $i(in vivo) ou $i(in vitro), chez des patients récepteurs de greffes de moelle osseuse et de cellules souches de sang périphérique, pendant le traitement de malignités relatives aux cellules bêta, telles que les lymphomes B ou les leucémies. Ledit agent de purge peut favoriser la prise de la greffe et/ou empêcher la rechute chez lesdits patients.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)